Reyhaneh Azizi - . Assistant Professor of Endocrinology, Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Nasim Namiranian - Assistant Professor of Community and Preventive Medicine, Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Saeedeh Jam Ashkezari - Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Miaad Hassani Kaboutarkhani - Medical Student, Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Somaye Gholami - Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Zahra Davoudi - Skull Base Research Center, Loghman Hakim Medical Center. Shahid Beheshti University of Medical Sciences, Tehran, Iran
Fatemeh Aghaei Meybodi - Assistant Professor, Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Objective: Pioglitazone is one of the oral medications of type ۲ diabetes (T۲DM). The purpose of this study was to evaluate the effect of pioglitazone on asthma and diabetes treatment outcomes among patients with concurrent asthma and T۲DM. Materials and Methods: We conducted a quasi-experimental study on ۱۱ patients with concurrent asthma and T۲DM in Yazd Afshar Hospital and Yazd diabetic research center ۲۰۱۴-۲۰۱۷. The inclusion criteria were patients between ۲۰-۶۰ years old, at least one year with concurrent asthma and T۲DM (documented with spirometer, bronchodilator test), ejection fraction more than ۵۰%. Patients who were smoker, on oral corticosteroids, phenobarbital, methotrexate, rifampin, phenytoin and gemfibrozil were excluded. Laboratory tests (FBS, HbA۱c, ۲hpp, leptin), spirometer test, exhaled nitric oxide were done before and after ۱۰ weeks of pioglitazone medication. All patients were visited every two weeks. The before and after pioglitazone treatment differences were checked by paired t-test and Wilcoxon Rank sum test. Results: The mean (± SD) age of participants was ۵۵.۸۱ (±۷.۶۶). The median of differences of leptin (p-value: ۰.۸۸۵), FEV۱ to FVC (P-value: ۰.۱۸۵), FEV۱ (p-value: ۰.۳۸۶), NO (P-value: ۰.۵۷۴), FVC percent (P-value: ۰.۴۷۷), FEV۱ percent (P-value: ۰.۵۱۵) did not differ before and after pioglitazone treatment.    Conclusion: Our finding suggested that pioglitazone may not be effective in the treatment and improvement of respiratory function in T۲DM with concurrent asthma.

Bronchial asthma, Thiazolidinedione, Diabetes mellitus-type